Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials

Rashmi B. Halker Singh, Ernesto Aycardi, Marcelo E. Bigal, Pippa S. Loupe, Mirna McDonald, David W. Dodick

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials'. Together they form a unique fingerprint.

Medicine & Life Sciences